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Take-home message: In patients with community-acquired pneumonia, the incidence of acute 
respiratory distress syndrome based on the Berlin definition was 2% among all patients in hospital, 
13% among patients in intensive care, and 29% among patients receiving mechanical ventilation. 
Acute respiratory distress syndrome was not related to the aetiology or mortality in this population. 
Take-home message: In mechanically-ventilated patients with community-acquired pneumonia, 
ARDS based on the Berlin criteria was not related to the aetiology or mortality. 
 ABSTRACT 
Question: To assess the incidence, characteristics, aetiology, risk factors and mortality of acute 
respiratory distress syndrome (ARDS) in ICU patients with community-acquired pneumonia (CAP) 
using the Berlin definition. 
Methods: We prospectively enrolled consecutive mechanically-ventilated ICU adults with CAP over 
20 years, compared with mechanically-ventilated patients without ARDS. The main outcome was 30-
day mortality.  
Results: Among 5,334 patients hospitalized with CAP, 930 (17%) were admitted to the ICU, and 432 
required mechanical ventilation; 125 (29%) cases met the Berlin ARDS criteria. ARDS was present in 
2% of hospitalized patients and 13% of ICU patients. Based on the baseline PaO2/FiO2, 60 (48%), 49 
(40%), and 15 (12%) patients had mild, moderate, and severe ARDS, respectively. Streptococcus 
pneumoniae was the most frequent pathogen, with no significant differences in aetiology between 
groups. Higher organ system dysfunction and previous antibiotic use were independent risk factors 
for ARDS in the multivariate analysis, while previous inhaled corticosteroids was independently 
associated with a lower risk. The 30-day mortality was similar between patients with and without 
ARDS (25% vs. 30%, p=0.25), confirmed by propensity-adjusted multivariate analysis. 
Conclusions: ARDS occurs as a complication of CAP in 29% of mechanically-ventilated patients, but is 
not related to the aetiology or mortality. 
 INTRODUCTION 
Community-acquired pneumonia (CAP) is associated with increased morbidity, mortality, 
and health costs [1,2]. The incidence of severe CAP requiring intensive care unit (ICU) admission is 
increasing, both because of septic shock and the need for invasive mechanical ventilation (IMV) [3]. 
Despite global efforts to improve outcomes, mortality remains high in severe CAP [4-6]. Streptococcus 
pneumoniae is the leading cause of CAP; it is the underlying etiological agent in 22% of patients 
requiring ICU admission [7], and approximately 30% of these patients develop pulmonary 
complications during their clinical courses [8]. 
Acute respiratory distress syndrome (ARDS) is a potential complication of severe CAP that is 
reported in approximately 3% of patients hospitalized with pneumococcal CAP [9]. This condition is 
characterized by the rapid development of severe acute respiratory failure, and is associated with 
high morbidity and mortality despite advances in supportive care and ventilator management [10,11]. 
However, there is limited information regarding the incidence of ARDS, associated pathogens, risk 
factors, and specific outcomes in hospitalized patients with severe CAP, especially in the era of the 
current Berlin definition, according to which patients must be receiving positive-pressure ventilation 
[12]. Although the overall survival from ARDS is improving [12,13], mortality remains as high as 35%, and 
disabling complications persist among ICU survivors, with recovery sometimes continuing for more 
than one year [13,14]. In addition, ARDS may be under recognized and undertreated [14]. 
We hypothesized that patients with severe CAP and ARDS have a higher mortality than those 
patients who require mechanical ventilation without ARDS. The aim of the study was to assess the 
incidence, clinical characteristics, aetiology, risk factors and mortality of ICU patients with severe 
CAP and ARDS according to the new Berlin definition [12], compared with ventilated patients without 
ARDS. 
 
METHODS 
Study design and patients 
Please refer to the online Supplemental Material for full details of the methods. This was a 
prospective observational cohort study of consecutive adult patients with CAP admitted to the ICU 
within 24 hours of hospital admission, between November-1996 and December-2016. The inclusion 
criteria were as follows: 1) met the criteria for severe CAP [15] and were admitted to the ICU, which 
included intermediate care units; and 2) received either IMV or non-invasive mechanical ventilation 
(NIMV) during the first 24 hours of hospital admission. Patients were excluded if they had severe 
immunosuppression or active tuberculosis. 
Data collection and evaluation 
The following were recorded at admission: age, sex, smoking history, alcohol and drug 
consumption, co-morbidities, antibiotic treatment in the 30 days before admission, treatment with 
oral and inhaled corticosteroids, clinical symptoms and signs, arterial blood gas measurements, and 
chest x-ray findings. All chest x-rays were reviewed by at least two co-authors, and consensus was 
required to define cases as ARDS or non-ARDS; we also assessed laboratory parameters, diagnostic 
procedures, empiric antibiotic therapy, ventilator support (IMV and NIMV), pulmonary 
complications, and other clinical events (cardiac arrhythmias, septic shock, and acute renal failure). 
Duration of treatment, length of hospitalization, and mortality were noted. Finally, we calculated the 
Pneumonia Severity Index (PSI) [16] and the Sepsis-related Organ Failure Assessment (SOFA) [17] scores 
 at hospital and ICU admissions. 
Microbiological evaluation and diagnostic criteria 
We collected sputum samples, and when available, pleural fluid, tracheobronchial aspirates, 
and bronchoalveolar lavage fluid. Sputum and blood samples were obtained for bacterial culture in 
the emergency department, before antibiotic therapy. Respiratory samples were processed for 
Gram and Ziehl–Neelsen stains and for bacterial, fungal, and mycobacterial cultures. 
Nasopharyngeal swabs for respiratory virus detection and urine samples for S. pneumoniae and 
Legionella pneumophila antigen detection were obtained within 24 hours of hospital admission. 
Blood samples for serology of atypical pathogens and respiratory viruses were taken at admission 
and in the third and sixth weeks thereafter. The criteria for etiological diagnosis can be found in a 
previous report [18]. 
Definitions 
Pneumonia was defined as a new pulmonary infiltrate on chest x-ray at hospital admission 
with symptoms and signs of lower respiratory tract infection. A prior episode of pneumonia was 
defined as a case within the past 12 months. 
ARDS was identified within the first 24 hours of hospital admission based on the Berlin 
definition [12]: new or worsening respiratory symptoms; bilateral pulmonary radiologic opacities, not 
fully explained by effusions; lobar/lung collapse or nodules, not fully explained by cardiac failure or 
fluid overload; and a PaO2/FiO2 (i.e., partial pressure of oxygen in arterial blood/fraction of inspired 
oxygen) ≤300 mmHg with a positive end-expiratory pressure or continuous positive airway pressure 
>5 cmH2O 
[12,19]. The severity of ARDS was divided into three categories: mild (200 <PaO2/FiO2 ≤300 
mmHg), moderate (100 <PaO2/FiO2 ≤200 mmHg) and severe (PaO2/FiO2 <100 mmHg) 
[12]. We chose 
the initial 24 hours to differentiate as ARDS and non-ARDS patients because this period of time is 
considered the limit to differentiate between clinical features at admission and worsening evolution 
in the hospital [20]. Chronic obstructive pulmonary disease (COPD) was defined according to the 
2017 GOLD strategy [21]. 
Clinical outcomes 
The primary outcome was 30-day mortality. Other outcomes were the hospitalization length, 
and the ICU and in-hospital mortality rates. Patients were followed for 30 days or until hospital 
discharge. 
Ethics statement 
The study was approved by the ethics committee of our institution (no. 2009/5451). The 
need for written informed consent was waived due to the non-interventional design. 
Statistical analysis 
Categorical variables are reported as number of patients (%), whereas continuous variables 
are reported as median (interquartile range [IQR]) for non-normal distributions or as mean (standard 
deviation [SD]) for normal distributions. Categorical variables were compared using the χ2 test or the 
Fisher exact test, and continuous variables were compared using the t-test or the nonparametric 
Mann–Whitney test, as appropriate. The significance level was p < 0.05 (2-tailed), unless otherwise 
specified. All analyses were performed using IBM SPSS Statistics, version 23.0 (IBM Corp., Armonk, 
NY, USA). 
  
 Logistic regression analyses [22] were used to examine the associations between ARDS and 
risk factors. First, each risk factor was tested individually. Second, all risk factors with an association 
in the univariate model (p < 0.15) were added to the multivariate model. Finally, a backward 
stepwise selection (pin < 0.05, pout < 0.10) was used to determine factors associated with ARDS. The 
association with 30-day mortality was tested by univariate and multivariate analyses with the same 
inclusion criterion (p < 0.15). 
A propensity score was developed for patients with ARDS [23]. Together with the year of 
occurrence of pneumonia, the presence of ARDS, the microbial aetiology, and the interaction 
between ARDS and the microbial aetiology, this was incorporated into the multivariate logistic 
regression analysis to predict 30-day mortality. If two independent variables were highly correlated 
(r > |±0.30|), the variable with the largest variance was excluded from multivariate analysis [24]. The 
odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. 
The Hosmer–Lemeshow goodness-of-fit test was performed to assess the overall fit of the 
models. The areas under the receiver operating characteristic curves (AUCs) of the multivariate 
models were calculated to predict ARDS and 30-day mortality. Internal validation of the prediction 
models was conducted by ordinary nonparametric bootstrapping with 1,000 bootstrap samples and 
bias-corrected, accelerated 95% CIs [25]. The same analyses were performed on the subset of patients 
with pneumococcal CAP. Finally, we used multiple imputation [26] to handle missing data. 
 
RESULTS 
Patients’ characteristics 
Among 5,334 patients hospitalized with CAP during the observation period, 930 (17%) were 
admitted to the ICU, of whom 462 (52%) were not ventilated, 137 (15%) received NIMV, and 295 
(33%) received IMV (Figure 1). 
The study population comprised 432 patients treated in ICU with either IMV or NIMV: 125 
cases (29%) met the Berlin ARDS criteria, and 307 cases (71%) did not. ARDS was present in 2% of all 
patients hospitalized with CAP and in 13% of those admitted to the ICU. According to the severity 
classification based on the baseline PaO2/FiO2 ratio, 60 (48%), 49 (40%), and 15 (12%) patients had 
mild, moderate, and severe ARDS, respectively. Two patients had been ventilated in the prone 
position. None of them had received extracorporeal membrane oxygenation. 
The patients’ characteristics are shown in Tables 1 and 2. Compared to patients without 
ARDS, those with ARDS had less frequently received treatment with inhaled corticosteroids; had less 
chronic respiratory co-morbidity, particularly COPD; had poorer baseline oxygenation, higher organ 
dysfunction, and lower PSI risk; and had more multilobar involvement. However, there was only a 
trend to have less frequently received pneumococcal vaccination, for less frequent male gender, and 
more frequent prior antibiotic treatment. 
Microbiological diagnosis 
An etiologic diagnosis was obtained in 228 patients (53%; Table 3). The most frequent 
pathogen in both groups was S. pneumoniae, with no significant differences in aetiology between 
the groups. Among the 100 cases of pneumococcal CAP, 29 met the ARDS criteria, the same 
proportion as in the overall population. 
  
 Empiric antibiotic therapy 
Data on empiric antibiotic treatment were available in 414 patients (96%; Online Table 1). 
The most frequent regimens were ß-lactam plus either a respiratory fluoroquinolone (42%) or a 
macrolide (31%). ARDS patients more often received a ß-lactam plus a respiratory fluoroquinolone 
compared with non-ARDS patients (p=0.003). 
Predictors of ARDS 
Among the variables associated with ARDS in the univariate analysis (Table 4), a higher SOFA 
score and previous antibiotic treatment remained significant independent risk factors for ARDS in 
the multivariate analysis. Interestingly, prior treatment with inhaled corticosteroids was 
independently associated with a lower risk for ARDS. The AUC was 0.66 (95% CI, 0.60–0.71) for the 
model predictive of ARDS (Online Figure 1). Internal validation of the logistic regression model by 
bootstrapping demonstrated robust results for all the variables in the model, with small 95% CIs 
around the original coefficients (Online Table 2). 
Mortality and length of stay 
We did not find significant differences between groups regarding mortality or length of 
hospitalization (Table 5). However, in cases with pneumococcal CAP, mortality in ICU was higher 
among those with ARDS (p=0.026; Online Table 3), but neither the in-hospital mortality (p=0.070) 
nor the 30-day mortality (p=0.088) reached statistical significance. 
According to ARDS severity, the 30-day mortality rate was 32%, 33%, and 60% for patients 
with mild, moderate and severe ARDS, respectively.  
Predictors of 30-day mortality 
Among the different variables associated with 30-day mortality in the univariate analysis 
(Table 6), the following were independent predictors of 30-day mortality in the propensity-adjusted 
multivariate analysis: older age, previous antibiotic treatment, other chronic pulmonary diseases 
(including only the sequelae of pulmonary tuberculosis, pulmonary hypertension, and interstitial 
lung disease), chronic cardiovascular and liver disease, higher SOFA score, and inadequate empiric 
antibiotic treatment. It was notable that having a previous episode of pneumonia and having 
received the pneumococcal vaccination were independently associated to a reduced 30-day 
mortality rates. 
Overall, ARDS was not associated with 30-day mortality, even after adjustment for potential 
confounders. The AUC was 0.79 (95% CI, 0.75–0.84) for the model predictive of 30-day mortality 
(Online Figure 2). Internal validation of the logistic regression model by bootstrapping with 
demonstrated robust results for all variables included in the model, with small 95% CIs around the 
original coefficients. Finally, the same analysis in the subset of patients with pneumococcal CAP 
confirmed that ARDS was not independently associated with 30-day mortality after adjustment for 
potential confounders (adjusted OR, 1.77; 95% CI, 0.70–4.50; p=0.23). 
 
DISCUSSION 
The main findings of this study are as follows. First, based on the Berlin definition, ARDS was 
present in 2% of all hospitalized patients with CAP, 13% of those admitted to the ICU, and 29% of 
those ICU patients requiring mechanical ventilatory support. Second, higher SOFA scores and 
previous antibiotic use were independent predictors for ARDS among ventilated patients with CAP, 
 while previous inhaled corticosteroid treatment was protective. Third, ARDS had no different 
aetiologies or mortality in patients requiring mechanical ventilation for CAP. 
ARDS is recognized globally as a major clinical problem [13], with pneumonia and 
extrapulmonary sepsis being the main risk factors in 75% of cases [14]. However, there has been a 
lack of information about the incidence of ARDS in CAP after the Berlin definition was proposed. Our 
data are consistent with those of the LUNG SAFE study [14], which evaluated the incidence of ARDS in 
459 ICUs in 50 countries. They reported that ARDS occurred in 10% of all ICU admissions and in 23% 
patients who required mechanical ventilation. According to the Berlin criteria, 30%, 47%, and 23% of 
their patients had mild, moderate, and severe ARDS, respectively. By contrast, there was a higher 
proportion of mild ARDS and a lower proportion of severe ARDS in our cohort. 
Over the past century only a few small case series of ARDS in pneumococcal CAP have been 
reported [27-29]. A recent French multicenter study [30] concerning pneumococcal CAP in the ICU 
indicated that the incidence of ARDS was 45%, which was substantially higher than that reported in 
this study. However, those authors used the prior American–European consensus definition of ARDS 
[31] and not the current Berlin definition, and included non-ventilated patients (16%). 
To our knowledge, this is the first study to provide data on the incidence of ARDS using the 
Berlin definition among patients hospitalized with CAP. We studied a cohort with severe CAP 
requiring mechanical ventilation, and compared those with and without ARDS. Regarding the 
independent predictors for ARDS, the association of higher organ system dysfunction to ARDS was to 
be expected because these patients had worse baseline oxygenation, an important component of 
the score.  
We previously reported that inhaled corticosteroid use before admission in patients 
hospitalized because of CAP can reduce the systemic inflammatory response [32], possibly 
with a selective modulation of the mechanisms of defences to infection [33], with reduced 
serum levels of tumour necrosis factor (TNF)-alpha, among others. This biomarker has been 
involved in the pathophysiology of ARDS [34]. 
We have no clear explanation for the independent association between previous antibiotic 
use and increased risk of ARDS. To our knowledge, this association has not previously been reported. 
We have shown that previous antibiotic use can be associated with antibiotic-resistant bacteraemia 
in patients with CAP [35], resulting in more inappropriate therapy. Whether this could predispose 
patients to ARDS remains to be assessed. However, this association requires confirmation in future 
studies. 
Mortality among ARDS patients was no different to that among ventilated non-ARDS 
patients. Indeed, even the propensity-adjusted multivariate analysis did not show an association 
between ARDS and patients’ mortality. According to our results, we think that the expected 
association of ARDS with mortality seems more related to the need for mechanical ventilation in 
these patients with CAP rather than ARDS itself, as we have recently reported that invasive 
mechanical ventilation in patients with severe CAP independently predicts mortality [36]. However, 
we cannot exclude that specific populations of patients with CAP and ARDS may have different 
mortality, since sub-phenotypes of ARDS patients with different outcomes related to inflammation 
[37] or fluid responsiveness [38] have recently been proposed. 
Independent predictors of mortality have previously been reported for CAP and other 
pulmonary infections in critically-ill patients, including older age, chronic liver disease [39], chronic 
cardiovascular disease [39-41], increased organ system dysfunction [42-44], and inadequate empiric 
 treatment [45]. It is not clear the reason for the association of previous pneumonia with lower 
mortality; possibly these patients might have developed a more effective immune response to 
infection. This is also consistent with pneumococcal vaccination being independently associated with 
reduced mortality. Given that ARDS was related to mortality in patients with pneumococcal 
pneumonia, previous vaccination might reduce disease severity in these patients. 
Due to the association of ARDS with higher mortality in pneumococcal pneumonia, there is a 
need to develop effective preventive measures for this complication. A recent randomized clinical 
trial [46] and a meta-analysis [47] found that short-term treatment with corticosteroids can prevent 
radiographic progression and ARDS development in CAP. However, these studies investigated CAP in 
general, not pneumococcal pneumonia specifically. Studies focusing on the acute treatment of 
pneumococcal pneumonia with corticosteroids or other immunomodulators [48] are therefore 
needed. Unfortunately, we have no systematic data on the number of patients who received 
pneumococcal conjugate vaccine-13 or pneumococcal polysaccharide vaccine-23. 
In our opinion, the strengths of this study are the large sample, the prospective and 
consecutive data collection, the use of the current Berlin definition for ARDS, and the statistical 
analysis by propensity scoring to account for bias due to observed confounders. We think this study 
provides reliable data on the incidence of ARDS in patients with severe CAP, and that these data can 
be used for future studies in this important population. In addition, we assessed the association of 
ARDS with mortality in mechanically-ventilated patients to avoid potential bias due to worse 
outcomes associated with the need for ventilatory support. 
Some limitations need to be addressed. First, the long period of recruitment (20 years) has 
undoubtedly been associated with major advances in patient care. Although we did incorporate 
advances in ventilatory management [10] and other support measures [13] over this time, our 
management protocol for CAP did not change substantially. We also allowed for this by including the 
period of admission when adjusting mortality outcomes. Second, this study was conducted at a 
single centre, which necessitates cautious extrapolation of the findings to other settings. Third, the 
Berlin definition requires the use of positive airway pressure, which is only applied to patients 
receiving ventilatory support. Fourth, the rate of respiratory viruses identified in our population may 
be underestimated since the diagnostic techniques employed were routinely implemented over the 
recruitment period.  
In conclusion, ARDS complicating severe CAP occurs in 29% of ventilated patients, but is 
unrelated to either the aetiology or mortality. ARDS criteria should not be considered in the choice 
of the empiric antibiotic treatment in these patients. 
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 FIGURE LEGEND 
Figure 1: Flow diagram of the study population.  
Abbreviations: ARDS = acute respiratory distress syndrome; CAP = community-acquired pneumonia; 
ICU = intensive care unit; IMV = invasive mechanical ventilation; NIMV = non-invasive mechanical 
ventilation. 
 
 
  
 Table 1: Characteristics of patients at baseline 
Variables  Non-ARDS patients 
n = 307 
ARDS patients  
n = 125 
p-value 
Age, mean (SD), years 65.8 (14.4) 63.1 (17.3) 0.26 
Male sex, n (%) 212 (69) 75 (60) 0.071 
Current smoker, n (%) 93 (31) 34/122 (28) 0.53 
Current alcohol abuse, n (%) 66 (22) 34 (28) 0.21 
Previous antibiotic, n (%) a 46 (17) 29 (25) 0.052 
Influenza vaccine, n (%) 66 (38) 26 (34) 0.62 
Pneumococcal vaccine, n (%) 33 (18) 7 (9) 0.054 
Inhaled corticosteroids, n (%) 80 (27) 18 (15) 0.008 
Systemic corticosteroids, n (%) 13 (6) 8 (8) 0.41 
Previous episode of pneumonia, n (%) 29 (11) 7 (6) 0.18 
Nursing home resident, n (%) 16 (5%) 5 (4%) 0.62 
Co-morbidity, n (%)b 244 (81) 83 (66) 0.002 
    Chronic respiratory disease 152 (51) 45 (37) 0.009 
        COPD 105 (36) 26 (22) 0.005 
        Asthma 9 (3) 4 (3) 0.89 
        Bronchiectasis 8 (3) 2 (2) 0.73 
        Other c 30 (10) 13 (11) 0.85 
    Chronic cardiovascular disease 52 (17) 20 (16) 0.76 
    Diabetes mellitus 75 (25) 26 (21) 0.38 
    Neurological disease 46 (16) 20 (17) 0.84 
    Chronic renal disease 27 (9) 8 (6) 0.37 
    Chronic liver disease 26 (9) 12 (10) 0.74 
Abbreviations: ARDS = acute respiratory distress syndrome; COPD = chronic obstructive pulmonary 
disease. Percentages were calculated for non-missing data. a Information on previous antibiotics was 
obtained in 67 (89%) cases without any significant differences in the type of antibiotics each group 
had received: beta-lactams (38 cases), Fluoroquinolons (12 cases), Macrolides (9 cases), and other (8 
cases). b Some patients may have more than 1 co-morbid condition. c Other respiratory diseases 
included the sequelae of pulmonary tuberculosis, pulmonary hypertension, and interstitial lung 
disease. 
 Table 2: Characteristics of patients at admission 
Variables  Non-ARDS patients 
n = 307 
ARDS patients  
n = 125 
p-value 
Mechanical ventilation, n (%)   0.55 
    Non-invasive 100 (33) 37 (30)  
    Invasive 207 (67) 88 (70)  
Laboratory findings, median (IQR)    
    Creatinine, mg/dL 1.3 (1; 1.8) 1.3 (0.9; 2) 0.52 
    C-reactive protein, mg/dL 20.7 (9.5; 30) 22.3 (14.8; 30.2) 0.15 
    PaO2/FiO2 233 (176; 296) 195 (151; 241) <0.001 
SOFA score, median (IQR)a 4 (3; 6) 5 (3; 6) 0.026 
PSI score, median (IQR) 123 (101; 143) 116 (81; 139) 0.017 
PSI risk class, n (%)b   0.020 
    I-III 42 (19) 29 (31)  
    IV-V 180 (81) 65 (69)  
Bacteremia, n (%) 46 (19) 20 (19) 0.98 
Pleural effusion, n (%) 65 (22) 22 (18) 0.37 
Multilobar, n (%) 97 (32) 125 (100) <0.001 
Septic shock, n (%) 106 (36) 45 (37) 0.87 
Acute renal failure, n (%) 140 (47) 61 (50) 0.63 
Abbreviations: ARDS = acute respiratory distress syndrome; IQR = interquartile range; PaO2/FiO2 = 
arterial oxygen tension to inspired oxygen fraction ratio; PSI = pneumonia severity index; SOFA = 
sepsis-related organ failure assessment. Percentages were calculated on non-missing data. a Higher 
SOFA in ARDS patients was due to a higher scoring in the respiratory component. b Stratified 
according to 30-day risk mortality for community-acquired pneumonia: risk classes I-III (≤90 points) 
have low predicted mortality (range, 0%-10%), and risk classes IV-V (>90 points) have the highest 
predicted mortality (range, 10%-35%). 
  Table 3: Microbial aetiology in the study population 
Pathogen Non-ARDS patients 
n = 307 
ARDS patients 
n = 125 
p-value 
Patients with defined aetiology 157 (51) 71 (57) 0.29 
Streptococcus pneumoniae 71 (45) 29 (41) 0.54 
Respiratory viruses 12 (8) 8 (11) 0.37 
Atypical  10 (6) 5 (7) >0.99 
 Mycoplasma pneumoniae 5 (3) 4 (6) 0.47 
 Coxiella burnetii 1 (1) 1 (1) 0.53 
 Chlamydophila pneumoniae 4 (3) 0 (0) 0.31 
Pseudomonas aeruginosa 10 (6) 3 (4) 0.76 
Staphylococcus aureus 8 (5) 4 (6) >0.99 
GNEB 5 (3) 3 (4) 0.71 
 Escherichia coli 3 (2) 3 (4) 0.38 
 Klebsiella pneumoniae 2 (1) 0 (0) >0.99 
Haemophilus influenzae 5 (3) 2 (3) >0.99 
Legionella pneumophila 2 (1) 4 (6) 0.077 
Streptococcus constellatus 1 (1) 0 (0) >0.99 
Moraxella catarrhalis 1 (1) 0 (0) >0.99 
Others 2 (1) 0 (0) >0.99 
Polymicrobiala 30 (19) 13 (18) 0.89 
Abbreviations: ARDS = acute respiratory distress syndrome; GNEB = Gram-negative enteric bacilli. 
Percentages calculated on non-missing data. 
The percentages of pathogens are related to the number of patients with etiologic diagnosis in each 
group. 
a Polymicrobial cases: S. pneumoniae + respiratory viruses; S. pneumoniae + H. influenzae; S. 
pneumoniae +atypical bacteria; S. pneumoniae + E. coli; S. pneumoniae + S. aureus, S. pneumoniae+ 
Acinetobacter spp.; S. pneumoniae +others, Respiratory viruses + H. influenzae; Respiratory viruses + 
S. aureus; Respiratory viruses + P. aeruginosa; Respiratory viruses + other; P. aeruginosa + L. 
pneumophila; P. aeruginosa + K. pneumoniae; P. aeruginosa + other; S. aureus+ M. Catarrhalis; S. 
aureus + atypical: S. aureus + P. aeruginosa. 
 
 Table 4: Significant univariate and multivariate logistic regression analyses of ARDS predictors 
Variable Univariatea Multivariatebc 
OR 95% CI p-value OR 95% CI p-value 
Year of occurrence of pneumonia ≥2007 0.96 0.64 to 1.46 0.86 0.99 0.64 to 1.54 0.98 
Age (+1 year) 0.99 0.98 to 1.00 0.12 - - - 
Female sex 1.49 0.97 to 2.29 0.071 1.52 0.97 to 2.39 0.067 
Pneumococcal vaccination 0.62 0.34 to 1.12 0.11 - - - 
Inhaled corticosteroids 0.45 0.26 to 0.77 0.004 0.48 0.27 to 0.85 0.012 
Previous antibiotic 1.60 0.99 to 2.61 0.057 1.80 1.08 to 2.98 0.024 
Previous episode of pneumonia 0.57 0.26 to 1.21 0.14 - - - 
Chronic respiratory diseased   0.076 - - - 
    Non-chronic respiratory disease 1 - - - - - 
    COPD 0.47 0.28 to 0.79 0.004 - - - 
    Asthma 0.72 0.27 to 1.92 0.51 - - - 
    Bronchiectasis 0.96 0.28 to 3.29 0.95 - - - 
    Othere 0.81 0.40 to 1.63 0.55 - - - 
SOFA score (+1 point)f 1.12 1.03 to 1.22 0.007 1.13 1.03 to 1.23 0.009 
Microbial etiology   0.36   0.37 
    Unknown  1 - - - - - 
    Streptococcus pneumoniae 1.10 0.67 to 1.82 0.70 1.17 0.69 to 1.97 0.56 
    Other 1.45 0.87 to 2.41 0.15 1.46 0.86 to 2.47 0.16 
 Abbreviations: ARDS = acute respiratory distress syndrome; CI = confidence interval; COPD = chronic obstructive pulmonary disease; OR = odds ratio; SOFA = 
sepsis-related organ failure assessment. Data are shown as estimated ORs (95% CIs) of the explanatory variables in the ARDS group. The OR is defined as the 
probability of having ARDS divided by the probability of not having ARDS. The p-value is based on the null hypothesis that all ORs relating to an explanatory 
variable equal unity (no effect). 
a The variables analyzed in the univariate analyses were as follows: age, gender, influenza and pneumococcal vaccination, systemic and inhaled 
corticosteroids, prior antibiotic treatment, chronic pulmonary disease, chronic cardiovascular disease, chronic renal disease, chronic liver disease, diabetes 
mellitus, neurological disease, pneumonia in the past year, nursing home resident, C-reactive protein, and SOFA score. 
b Adjusted for the propensity score, the year of occurrence of pneumonia, and the microbial etiology. 
c Hosmer–Lemeshow goodness-of-fit test, p = 0.35. 
d The p-value corresponds to differences between the five groups (non-chronic respiratory disease, COPD/chronic bronchitis, asthma, bronchiectasis, or 
other chronic respiratory diseases). 
e Other chronic respiratory diseases include sequelae of pulmonary tuberculosis, pulmonary hypertension, and interstitial lung disease. 
f The p-value corresponds to differences between the three groups (unknown etiology, Streptococcus pneumoniae, or other etiologies). 
 
 Table 5: Clinical Outcomes 
Variables  Non-ARDS patients 
n = 307 
ARDS patients  
n = 125 
p-value 
Length of hospital stay, median (IQR), days 15 (10; 27) 16 (9; 30) 0.96 
ICU mortality, n (%) 70 (23) 37 (30) 0.14 
In-hospital mortality, n (%) 81 (26) 41 (33) 0.18 
30-day mortality, n (%) 90 (30) 44 (35) 0.25 
Abbreviations: ARDS = acute respiratory distress syndrome; ICU = intensive care unit; IQR = 
interquartile range. Percentages were calculated for non-missing data. 
 
 Table 6: Significant univariate and multivariate logistic regression analyses for predictors of 30-day mortality 
Variable Univariatea Multivariatebc 
OR 95% CI p-value OR 95% CI p-value 
Year of occurrence of pneumonia ≥2007 0.56 0.37 to 0.84 0.005 0.69 0.42 to 1.14 0.15 
Age (+1 year) 1.02 1.01 to 1.04 0.002 1.03 1.01 to 1.05 0.002 
Pneumococcal vaccination 0.50 0.27 to 0.92 0.025 0.38 0.18 to 0.82 0.013 
Previous antibiotic 1.50 0.92 to 2.42 0.10 2.09 1.17 to 3.72 0.012 
Previous episode of pneumonia 0.43 0.20 to 0.96 0.039 0.33 0.14 to 0.81 0.016 
Chronic respiratory diseased   0.017   0.040 
    Non-chronic respiratory disease 1 - - - - - 
    COPD 0.94 0.58 to 1.50 0.78 0.85 0.46 to 1.59 0.62 
    Asthma 0.37 0.11 to 1.28 0.12 0.28 0.06 to 1.26 0.096 
    Bronchiectasis 0.77 0.20 to 2.92 0.70 0.77 0.17 to 3.46 0.74 
    Othere 2.53 1.31 to 4.89 0.006 2.42 1.09 to 5.35 0.029 
Chronic cardiovascular disease 2.11 1.26 to 3.53 0.005 1.97 1.07 to 3.61 0.029 
Chronic liver disease 2.58 1.33 to 5.01 0.005 2.35 1.09 to 5.06 0.029 
Diabetes mellitus 1.42 0.89 to 2.26 0.14 - - - 
SOFA score (+1 point) 1.28 1.17 to 1.40 <0.001 1.25 1.09 to 1.43 0.001 
Inadequate antibiotic therapy 2.72 1.59 to 4.65 <0.001 2.55 1.30 to 4.99 0.006 
Microbial aetiology f   0.15   0.30 
    Unknown  1 - - 1 - - 
 Variable Univariatea Multivariatebc 
OR 95% CI p-value OR 95% CI p-value 
    Streptococcus pneumoniae 1.44 0.89 to 2.34 0.14 1.57 0.78 to 3.16 0.20 
    Others 1.58 0.95 to 2.61 0.078 1.60 0.78 to 3.28 0.20 
ARDS 1.31 0.84 to 2.04 0.23 1.06 0.49 to 2.32 0.88 
Interaction microbial etiology × ARDSg   0.33   0.65 
    Streptococcus pneumoniae × ARDS 1.62 0.56 to 4.69 0.38 1.64 0.48 to 5.53 0.43 
    Other × ARDS 0.67 0.22 to 1.99 0.47 0.93 0.27 to 3.21 0.90 
Abbreviations: ARDS = acute respiratory distress syndrome; CI = confidence interval; OR = odds ratio; PSI = pneumonia severity index; SOFA = sepsis-related 
organ failure assessment. Data are shown as estimated ORs (95% CIs) of the explanatory variables in the 30-day mortality group. The OR is defined as the 
probability of 30-day mortality divided by the probability of no 30-day mortality. The p-value is based on the null hypothesis that all ORs relating to an 
explanatory variable equal unity (no effect). 
a The variables analyzed in the univariate analyses were: age, gender, influenza and pneumococcal vaccination, systemic and inhaled corticosteroids, prior 
antibiotic treatment, chronic pulmonary disease, chronic cardiovascular disease, chronic renal disease, chronic liver disease, diabetes mellitus, neurological 
disease, pneumonia in the past year, nursing home resident, creatinine, C-reactive protein, SOFA score, and inadequate antibiotic therapy. 
b Adjusted for the propensity score, the year of occurrence of pneumonia, the ARDS, the microbial etiology, and the interaction between ARDS and 
microbial etiology. 
c Hosmer-Lemeshow goodness-of-fit test, p = 0.27. 
d The p-value corresponds to differences between the five groups (non-chronic respiratory disease, COPD/chronic bronchitis, asthma, bronchiectasis, or 
other chronic respiratory diseases). 
e Other chronic respiratory diseases include sequelae of pulmonary tuberculosis, pulmonary hypertension, and interstitial lung disease. 
f The p-value corresponds to differences between the three groups (unknown etiology, Streptococcus pneumoniae, or other etiologies). 
g The p-value corresponds to the interaction between microbial etiology and ARDS. 
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 Extended methods 
Study design and patients 
We performed a prospective observational cohort study of consecutive adult patients with 
community-acquired pneumonia (CAP) who were transferred to our intensive care unit (ICU) within 
24 hours of hospital admission. The study was conducted between November 1996 and December 
2016 at the Hospital Clinic, Barcelona, which is a 700-bed tertiary care university hospital. The 
inclusion criteria were as follows: 1) patients meeting the Infectious Disease Society of 
America/American Thoracic Society (IDSA/ATS) criteria for severe CAP [1] who were admitted to the 
ICU, including associated intermediate care units; and 2) patients who received either invasive 
mechanical ventilation (IMV) or non-invasive mechanical ventilation (NIMV) during the first 24 hours 
of hospital admission. Patients were excluded if they had active tuberculosis or severe 
immunosuppression. The latter included the following: neutropenia after chemotherapy or 
hematopoietic transplantation; drug-induced immunosuppression because of solid-organ 
transplantation, long-term corticosteroid treatment (>10 mg/day), or cytotoxic therapy; and all 
patients infected with HIV. 
Data collection and evaluation 
The following parameters were recorded at admission: age, sex, smoking, alcohol and drug 
consumption, co-morbidities, antibiotic treatment in the 30 days before hospital admission, 
treatment with oral and inhaled corticosteroids, clinical signs and symptoms, arterial blood gas 
measurements, chest radiograph findings. Co-morbidities included chronic respiratory disease (e.g., 
chronic obstructive pulmonary disease [COPD], asthma, and bronchiectasis), diabetes mellitus, and 
chronic cardiovascular, neurological, renal, or liver disease. Clinical symptoms of interest were fever, 
cough, pleuritic chest pain, dyspnea, mental confusion, and aspiration, while signs of interest were 
blood pressure, body temperature, respiratory rate, and heart rate. 
All chest x-rays were reviewed by at least two co-authors, either as part of the medical team of the 
ICU (MF, GLB, AT) or as attending physicians (AC, OR, CGV). For chest x-rays, we recorded the 
number of lobes affected, and the presence or absence of pleural effusion and atelectasis. 
Agreement by at least two co-authors was required to define a case as acute respiratory distress 
syndrome (ARDS) or non-ARDS. 
We also assessed laboratory parameters (e.g., hemoglobin level, white blood cell count, platelet 
count, serum creatinine, and C-reactive protein), diagnostic procedures, empiric antibiotic therapy, 
ventilatory support (IMV and NIMV), pulmonary complications (e.g., empyema, pleural effusion, and 
surgical pleural draining), other clinical events (e.g., cardiac arrhythmias, septic shock, and acute 
renal failure). The duration of treatment, length of hospitalization, and mortality were also noted. 
Finally, we calculated the Pneumonia Severity Index (PSI) [2] and the Sepsis-related Organ Failure 
Assessment (SOFA) [3] scores at hospital and ICU admissions. 
Microbiological evaluation and diagnostic criteria 
Microbiological examination was performed in sputum, urine, nasopharyngeal swabs and two blood 
samples. Pleural puncture, tracheobronchial aspirates and bronchoalveolar lavage fluid, when 
available, were collected for Gram and Ziehl–Neelsen stains, and for bacterial, fungal, and 
mycobacterial cultures. 
Lower respiratory tract samples and blood samples were obtained in the emergency department for 
bacterial culture before the start of antibiotic therapy. Nasopharyngeal swabs for respiratory virus 
 detection and urine samples for S. pneumoniae and Legionella pneumophila antigen detection were 
obtained within 24 hours of hospital admission. Blood samples for atypical pathogen and respiratory 
virus serology were taken at admission and in the third and sixth weeks thereafter. The criteria used 
for etiological diagnosis have been reported previously [4]. 
Definitions 
Pneumonia was defined as a new pulmonary infiltrate on chest x-ray at hospital admission, with 
symptoms and signs compatible with a lower respiratory tract infection. A prior episode of 
pneumonia was defined as a case of pneumonia within the past 12 months. Severe CAP was defined 
according to when at least one major or three minor criteria of the IDSA/ATS guidelines were 
present [1] or if the patient was admitted to the ICU. 
ARDS was identified by applying the Berlin definition in the first 24 hours after hospital admission 
[5]: new or worsening respiratory symptoms, bilateral pulmonary radiologic opacities not fully 
explained by effusions, lobar/lung collapse or nodules and not fully explained by cardiac failure or 
fluid overload, and a PaO2/FiO2 (i.e., partial pressure of oxygen in arterial blood/fraction of inspired 
oxygen) ≤300 mmHg with a positive end-expiratory pressure or continuous positive airway pressure 
>5 cmH2O [5,6]. The severity of ARDS was divided into three categories: mild (200 < PaO2/FiO2 ≤300 
mmHg), moderate (100 < PaO2/FiO2 ≤ 200 mmHg) and severe (PaO2/FiO2 < 100 mmHg) [5]. We chose 
the initial 24 hours to differentiate as ARDS and non-ARDS patients because this period of time is 
considered the limit to differentiate between clinical features at admission and worsening evolution 
in the hospital [7]. COPD was defined according to the criteria of the 2017 GOLD strategy [8]. 
Clinical outcomes 
The primary outcome was 30-day mortality. Other outcomes were the hospitalization length, and 
the ICU and in-hospital mortality rates. Patients were followed for 30 days or until hospital 
discharge, whichever was the longest period. 
Ethics statement 
The study was approved by the ethics committee of our institution (no. 2009/5451). The need for 
written informed consent was waived due to the non-interventional design. 
Statistical analysis 
All analyses were performed using IBM SPSS Statistics version 23.0 (IBM Corp., Armonk, NY, USA). 
The level of significance was set at 0.05 (2-tailed), unless otherwise specified. We used a logistic 
regression model to identify factors associated with ARDS (1). Factors were included in the 
multivariate model when univariate comparisons yielded a level of significance of p < 0.15. We 
tested the following variables: age (years), gender (male vs female), influenza and pneumococcal 
vaccination status (no vs yes), systemic and inhaled corticosteroid use (no vs yes), prior antibiotic 
treatment (no vs yes), chronic pulmonary disease (no disease vs. COPD vs chronic bronchitis vs 
asthma vs bronchiectasis vs other), chronic cardiovascular disease (no vs yes), chronic renal disease 
(no vs yes), chronic liver disease (no vs yes), diabetes mellitus (no vs yes), neurological disease (no vs 
yes), pneumonia in the past year (no vs yes), nursing home resident (no vs yes), C-reactive protein 
(mg/dL), and SOFA score (points). A backward stepwise selection (pin < 0.05, pout < 0.10) was used to 
identify factors predictive of ARDS. 
The factors associated with the 30-day mortality were also assessed by univariate and multivariate 
analyses (using the same inclusion criterion, p < 0.15). Inadequate antibiotic therapy (no vs yes) was 
also tested for 30-day mortality. A propensity score for patients with ARDS was developed (2), 
 irrespective of the outcome, through a multivariate logistic regression to predict the influence of the 
14 predetermined variables on the presence of ARDS. We included variables in the propensity score 
calculation based on the methods of Brookhart et al. (3), plus any variables associated with ARDS 
and clinical outcomes. Finally, we performed a logistic regression analysis to predict 30-day mortality 
by incorporating the propensity score, the year of occurrence of pneumonia, the presence of ARDS, 
the microbial etiology, and the interaction between ARDS and microbial etiology. This included all 
risk factors with an association in the univariate analyses (p < 0.15), calculated in a stepwise 
backward elimination procedure (pin < 0.05, pout < 0.10). To identify collinearity, we calculated the r 
coefficient between two independent variables, and if they were highly correlated (r >|±0.30|), the 
variable with the largest variance was excluded from multivariate analysis (4) The analyses were 
repeated for the subset of patients with pneumococcal CAP. 
We investigated the missing data patterns for covariates and assumed missing at random condition 
for covariates (5). We then used multiple imputation (6) to generate five datasets to evaluate the 
prediction performance for ARDS and 30-day mortality. The model for multiple imputation included 
all covariates of the risk models, plus ARDS and 30-day mortality. To simplify the performance 
evaluation, we filled in missing values with the first set of imputed values from the multiple 
imputation. 
 Online Table 1: Empiric antibiotic treatment in the study population 
Therapy Non-ARDS patients 
n = 307 
ARDS patients 
n = 125 
p-value 
Fluoroquinolones monotherapy 16 (5) 3 (2) 0.18 
β-lactam monotherapy 15 (5) 3 (2) 0.22 
Macrolide monotherapy 2 (1) 0 (0) >0.99 
Glycopeptide monotherapy 0 (0) 1 (1) 0.30 
β-lactam plus fluoroquinolone 110 (38) 65 (53) 0.003 
β-lactam plus macrolide 95 (33) 35 (29) 0.44 
β-lactam plus aminoglycoside 17 (6) 3 (3) 0.15 
Other combinations 37 (13) 12 (10) 0.42 
Inappropriate empiric treatment a 21 (17) 4 (7) 0.070 
Abbreviations: ARDS = acute respiratory distress syndrome. Percentages were calculated for non-
missing data. 
a Calculated among patients with defined aetiology only. 
The percentages of therapies are related to the numbers of patients receiving empiric antibiotic 
treatment in each group (292 patients in the non-ARDS group and 122 patients in the ARDS group). 
 Online Table 2: Internal validation of the prediction model for ARDS, using the nonparametric 
bootstrap technique 
Variable Original Bias SE 95% BCa CI 
Year of occurrence of pneumonia ≥2007 -0.007 0.004 0.238 -0.457 to 0.482 
Male sex 0.421 0.008 0.241 -0.050 to 0.924 
Inhaled corticosteroids -0.726 -0.037 0.307 -1.356 to -0.236 
Previous antibiotic 0.585 0.010 0.280 0.040 to 1.168 
SOFA score 0.118 0.001 0.047 0.027 to 0.214 
Microbial aetiology     
 Streptococcus pneumoniae 0.156 -0.012 0.280 -0.395 to 0.687 
 Other 0.377 0.001 0.271 -0.137 to 0.877 
Abbreviations: ARDS = acute respiratory distress syndrome; BCa = adjusted bootstrap; CI = 
confidence interval; SE = standard error; SOFA, sepsis-related organ failure assessment. 
 Online Table 3. Clinical outcomes of pneumococcal CAP 
Variables  Patients with 
non-ARDS 
n = 88 
Patients with 
ARDS 
n = 35 
p-value 
Length of hospital stay, median (IQR), days 15.5 (11; 31.5) 15 (9; 31) 0.46 
ICU mortality, n (%) 18 (20) 14 (40) 0.026 
In-hospital mortality, n (%) 23 (26) 15 (43) 0.070 
30-day mortality, n (%) 26 (30) 16 (46) 0.088 
Abbreviations: ARDS = acute respiratory distress syndrome; CAP = community-acquired 
pneumonia; ICU = intensive care unit; IQR = interquartile range. 
Percentages calculated on non-missing data. 
 
 Online Figure 1: ROC curve analysis of significant variables derived from the logistic 
regression model to predict ARDS 
 
 
Abbreviations: AUC indicates area under the curve; ARDS = acute respiratory distress 
syndrome; CI, confidence interval; ROC, receiver operating characteristic. 
 Online Figure 2. ROC curve analysis of significant variables derived from the logistic 
regression model to predict 30-day mortality 
 
 
Abbreviations: AUC indicates area under the curve; CI, confidence interval; ROC, receiver 
operating characteristic. 
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